Tag archive for ‘Alimera third quarter results’
Alimera : Changing from A Buy to Hold (ALIM, $1.20, Hold)
After four years of following Alimera and never having a Buy on the Company, I upgraded to a Buy in a report published on June 21, 2017: Iluvien Sales Seem to Have Caught Traction; It Is Time to Buy! (ALIM, Buy, $1.35). The basis for my upgrade was two-fold. Very importantly US unit growth for Iluvien […]